Bright Minds Biosciences (DRUG) Price & Analysis

Compare

229 Followers

DRUG Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.93 - $79.02

Previous Close$40.4

Volume34.65K

Average Volume (3M)29.45K

Market Cap

C$205.18M

Enterprise ValueN/A

Total Cash (Recent Filing)C$57.90M

Total Debt (Recent Filing)C$182.73K

Price to Earnings (P/E)―

Beta4.70

Next Earnings

Sep 01, 2025

EPS Estimate

-0.49

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.31

Shares Outstanding7,083,239

10 Day Avg. Volume34,956

30 Day Avg. Volume29,449

Financial Highlights & Ratios

PEG Ratio-4.12

Price to Book (P/B)4.96

Price to Sales (P/S)0.00

P/FCF Ratio-129.99

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

C$86.00

Price Target Upside196.45% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

Bright Minds Biosciences News

See All News >

Bulls Say, Bears Say

Bulls Say

Financial StabilityBright Minds Biosciences has an adequate cash position to support operations for the next 12 months, indicating financial stability.

Market PotentialThe Phase 2 BREAKTHROUGH program is advancing toward a readout in both absence epilepsy and developmental and epileptic encephalopathies, indicating strong potential to unlock value across a large, underserved treatment-resistant epilepsy market.

Therapeutic ProfileThe unique Gq-biased 5-HT2C mechanism and robust preclinical and Phase 1 dataset of BMB-101 distinguish it from peers, supporting a best-in-class therapeutic profile.

Bears Say

Clinical RiskThe clinical risk remains very high given the limited data available.

Financial ConcernsThe company only has approximately $30M of cash on hand, thus it will need to raise money in the near-term which may significantly dilute current shareholders.

Financials

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

30.98% Insiders

0.05% Mutual Funds

47.89% Other Institutional Investors

20.88% Public Companies and

Individual Investors

Detailed Ownership Overview >

DRUG FAQ

What was Bright Minds Biosciences’s price range in the past 12 months?

Bright Minds Biosciences lowest stock price was $0.93 and its highest was $79.02 in the past 12 months.

What is Bright Minds Biosciences’s market cap?

Bright Minds Biosciences’s market cap is C$205.18M.

When is Bright Minds Biosciences’s upcoming earnings report date?

Bright Minds Biosciences’s upcoming earnings report date is Sep 01, 2025 which is in 96 days.

How were Bright Minds Biosciences’s earnings last quarter?

Bright Minds Biosciences released its earnings results on May 15, 2025. The company reported -$0.306 earnings per share for the quarter, beating the consensus estimate of -$0.331 by $0.025.

Is Bright Minds Biosciences overvalued?

According to Wall Street analysts Bright Minds Biosciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Bright Minds Biosciences pay dividends?

Bright Minds Biosciences does not currently pay dividends.

What is Bright Minds Biosciences’s EPS estimate?

Bright Minds Biosciences’s EPS estimate is -0.49.

How many shares outstanding does Bright Minds Biosciences have?

Bright Minds Biosciences has 7,083,239 shares outstanding.

What happened to Bright Minds Biosciences’s price movement after its last earnings report?

Bright Minds Biosciences reported an EPS of -$0.306 in its last earnings report, beating expectations of -$0.331. Following the earnings report the stock price went up 1.978%.

Which hedge fund is a major shareholder of Bright Minds Biosciences?

Currently, no hedge funds are holding shares in DRUG

Bright Minds Biosciences Stock Smart Score

Neutral

Fundamentals

Return on Equity

-11.21%

Trailing 12-Months

Asset Growth

764.61%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Bright Minds Biosciences

Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.

DRUG Stock 12 Month Forecast

Average Price Target

$86.00

▲(196.45%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","93":"$93","23.25":"$23.3","46.5":"$46.5","69.75":"$69.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":92.99999972513665,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$93.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":85.9994752,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$86.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":79.9999997635584,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$80.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,23.25,46.5,69.75,93],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Oct<br/>2024","9":"Jan<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,30.62,35.41846151731821,40.21692303463641,45.01538455195461,49.81384606927281,54.612307586591015,59.41076910390922,64.20923062122742,69.00769213854562,73.80615365586382,78.60461517318203,83.40307669050023,88.20153820781844,{"y":92.99999972513665,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,30.62,34.879959630769235,39.139919261538466,43.3998788923077,47.65983852307693,51.91979815384616,56.17975778461539,60.43971741538462,64.69967704615385,68.95963667692308,73.21959630769231,77.47955593846154,81.73951556923078,{"y":85.9994752,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,30.62,34.41846152027372,38.21692304054745,42.015384560821175,45.813846081094894,49.61230760136861,53.410769121642346,57.209230641916065,61.007692162189784,64.80615368246352,68.60461520273724,72.40307672301095,76.20153824328469,{"y":79.9999997635584,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.38,"date":1711929600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.04,"date":1714521600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.21,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.05,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.15,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.06,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.1,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":48.18,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":48.18,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.02,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.11,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.62,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >